tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and Insulet (PODD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aerie Pharma (AERIResearch Report) and Insulet (PODDResearch Report).

Aerie Pharma (AERI)

Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma today and set a price target of $22.00. The company’s shares closed last Thursday at $6.86, close to its 52-week low of $6.39.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.2% and a 38.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $18.00, a 162.4% upside from current levels. In a report issued on January 14, Stifel Nicolaus also maintained a Buy rating on the stock with a $27.00 price target.

See today’s best-performing stocks on TipRanks >>

Insulet (PODD)

In a report released today, Marie Thibault from BTIG maintained a Hold rating on Insulet. The company’s shares closed last Thursday at $194.80, close to its 52-week low of $193.70.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 20.7% and a 33.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.

Insulet has an analyst consensus of Moderate Buy, with a price target consensus of $315.44.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AERI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed